FOR IMMEDIATE RELEASE: Paradigm Clinical Research Now Enrolling for Pediatric RSV Clinical Trial

Modesto, CA – March 10, 2025 – Paradigm Clinical Research is now enrolling children under five years old in a clinical trial for Respiratory Syncytial Virus (RSV), a common but potentially serious virus affecting young children. This research study, sponsored by Gilead Sciences, aims to evaluate an investigational treatment for RSV, offering families access to expert medical care and no-cost testing.

RSV can lead to severe complications, particularly for high-risk groups, including:

• Premature infants
• Infants 6 months and younger
• Children with congenital heart or chronic lung disease
• Children with neuromuscular conditions

Eligible participants must be under five years old, diagnosed with RSV, not currently hospitalized, and enrolled within three days of symptom onset. Symptoms of RSV include cough, nasal congestion, rapid breathing, and runny nose.

Why consider this clinical trial?

? Access to investigational RSV treatment
? Expert medical care during the study
? No-cost RSV testing

"Early diagnosis and treatment are critical in managing RSV," said Joshua Binns, Site Manager at Paradigm Clinical Research. "We encourage parents who suspect RSV in their child to contact us immediately to learn more about this study opportunity."

For more information or to see if your child qualifies, visit www.paradigm-research.com, call (209) 554-4844, or email modesto@paradigm-research.com.

About Paradigm Clinical Research

Paradigm Clinical Research is dedicated to advancing medical knowledge and improving patient outcomes through clinical trials. Our experienced team works closely with sponsors and the local community to provide access to cutting-edge research opportunities.

Media Contact:

Joshua Binns
Site Manager, Paradigm Clinical Research
Email: modesto@paradigm-research.com
Phone: (209) 554-4844